Streetbeat News

Stock Prices

NIO

Nio reported Q1 2023 vehicle deliveries of 31,041, a 20.5% increase YoY but a 22.5% decrease compared to Q4 2022. The company expects Q2 deliveries to be between 23,000 and 25,000 vehicles.

Portfolio Pulse from Charles Gross

June 09, 2023 | 10:07 am

TOUR

Tuniu Corporation (NASDAQ:TOUR) reported Q1 sales of $9.20 million, a 40.59% increase from $6.54 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 10:04 am

PATH

Wells Fargo analyst Michael Turrin downgraded UiPath (NYSE:PATH) from Overweight to Equal-Weight and announced a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

June 09, 2023 | 9:58 am

GM

TSLA

Tesla's stock shows strong upward momentum, eyeing its best winning streak since January 2021. General Motors partners with Tesla to use its charging infrastructure, and Tesla is in talks with regional government leaders in Valencia, Spain, and the Mongolian Prime Minister for potential automotive investments.

Portfolio Pulse from Shanthi Rexaline

June 09, 2023 | 9:37 am

BIDU

Baidu, Inc. has announced the launch of its RMB counter, effective on June 19, 2023. The company will become a security with counters denominated in HKD and RMB, designated as a dual counter security by the Stock Exchange.

Portfolio Pulse from Charles Gross

June 09, 2023 | 9:12 am

ELEV

Elevation Oncology has priced its public offering of 17.81 million shares, pre-funded warrants to purchase up to 4.44 million shares, and accompanying warrants at a combined offering price of $2.25, raising approximately $50 million.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 8:28 am

EDIT

Editas Medicine announced positive initial safety and efficacy data from the first four patients with sickle cell disease treated with EDIT-301 in the RUBY trial and the first transfusion-dependent beta thalassemia patient treated in the EdiTHAL trial.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:30 am

KYMR

Kymera Therapeutics (NASDAQ:KYMR) will present preclinical data on KT-253, a potent and selective heterobifunctional MDM2 degrader, at the European Hematology Association Congress from June 8-15, 2023.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:29 am

ABBV

AbbVie announced new findings demonstrating sustained long-term safety and efficacy of VENCLYXTO/VENCLEXTA-based combination therapies in patients with previously untreated CLL with co-existing conditions, as well as R/R CLL. The results are being presented at the EHA Annual Congress in Frankfurt, Germany.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:25 am

CRSP

VRTX

Vertex Pharmaceuticals and CRISPR Therapeutics announced positive results from pivotal trials of exa-cel for transfusion-dependent beta thalassemia and severe sickle cell disease. Both trials met primary and key secondary endpoints at pre-specified interim analyses.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 7:21 am